Skip to main content
Download PDF

Attitudes toward an HPV vaccine for condyloma acuminata and willingness to undergo vaccination among STD clinic attendees in China: Focus on STI prevention with HPV vaccine

BMC Public Health volume 24, Article number: 1610 (2024) Cite this article

Abstract

Background

Condyloma acuminata (CA) is a common, and recurrent sexually transmitted disease (STD) that greatly contributes to direct health care costs and has a substantial psychosocial impact. Human papillomavirus (HPV) vaccination (containing L1 protein for HPV types 6 and 11) effectively controls CA.

Objectives

We investigated attitudes toward the HPV vaccine for CA and willingness to undergo vaccination among STD clinic attendees in China.

Methods

Attendees at STD clinics at two selected hospitals in Guangdong and Jiangsu Provinces from May to September 2017 were requested to complete a self-administered questionnaire for this cross-sectional study.

Results

The participants’ median age was 28 years (IQR: 24.0–34.0), and the sex ratio was balanced; 63.5% were from Guangdong, 36.5% were from Jiangsu, and 44.5% had a history of CA. The vaccine acceptance rate was high among the participants (85.8%,235/274) to whom the HPV vaccine for CA was available, especially among those who had heard of CA (89.0%, AOR = 3.14, 95% CI: 1.29–7.63, p = 0.0114). 95 (34.7%) of 274 participants had a positive attitude toward the HPV vaccine for CA. STD clinic attendees who had heard of the connection between HPV and CA (AOR = 2.56, 95% CI: 1.31-5.00, p = 0.0060), had heard of the HPV vaccines or cervical cancer vaccines (AOR = 1.90, 95% CI: 1.02–3.54, p = 0.0444) and had ever proactively discussed CA or the vaccine with others (AOR = 1.95, 95% CI:1.00-3.79, p = 0.0488) had better attitudes toward the HPV vaccine for CA. Over half of the participants (52.5%) expected the price of the HPV vaccine for CA to be under $90.

Conclusion

The acceptance of the HPV vaccine for CA was high among STD clinic attendees in China, and the participants’ self-perceived knowledge of CA and HPV was associated with better attitudes toward the HPV vaccine for CA. Education to improve knowledge is vital for reducing vaccine hesitancy.

Peer Review reports

Introduction

Human papillomavirus (HPV) is known to be associated with various cancers, especially cervical cancer. In 2018, 13% of cancer cases worldwide were attributable to infection, and HPV infection accounted for 31% of all infection-related incident cancer cases [1]. Cervical cancer is the most common HPV-attributable cancer, accounting for 80%; over 95% of cervical cancer cases from HPV infection [2]. China is one of the countries in great part responsible for the cases, with approximately 0.11 million cases [2]. ​Therefore, many people in China associate HPV with cervical cancer, however, HPV also causes condyloma acuminata (CA, also known as anogenital warts or genital warts). Despite cancer being a priority, we are also concerned about the neglected disease burden caused by CA [3]. Notably, CA is potentially an important co-factor in HIV transmission [4, 5].

CA is a frequently identified clinical symptom of low-risk HPV infection. HPV type 6 (HPV-6) and HPV-11 are associated with approximately 90% of CA cases [6]. The reported incidence of CA in China (0.24–0.29/1000 person years) is lower than that in the general population worldwide (1.6–2.9/1000 person years). However, the true disease burden associated with CA in China, is seriously underestimated due to incomplete disease surveillance and registration systems [7,8,9]. Furthermore, CA often recurs after initial remission is achieved and requires repeated treatments, with recurrence rates ranging from 6–77% [10]. Although CA is the most frequent benign lesion and is not life-threatening, it is a common problem with a considerable impact on health-care costs; additionally, CA is a source of tremendous psychological pressure and declining patient quality of life [3, 11, 12]. CA is worthy of further attention in high-risk STD populations.

Vaccination has become an effective preventive tool for precancerous lesions and CA. As of September 2023, 64% WHO member states have incorporated the HPV vaccine into their national immunization schedules. Predominantly, these are high-income and upper-middle-income countries; however, many of the world’s most populous nations have not yet included the HPV vaccine in their immunization regimes, with only 12% of females and 6% of males having received the first dose as of 2022 [13]. Despite the increased introduction of the HPV vaccine in low-income and lower-middle-income countries (LLMICs) with the support of Gavi, a persistent global shortage of the HPV vaccine has led to concerns that supply may not meet the increasing worldwide demand. Furthermore, while some nations have embraced a gender-neutral vaccination policy, targeting both boys and girls, the LLMICs primary emphasis continues to be on vaccinating girls aged 9–10 years, a practice that contrasts with the broader age range targeted in developed countries.

HPV vaccines were introduced in mainland China in 2016 [14]. A bivalent vaccine (2vHPV, Cervarix®), and a quadrivalent vaccine (4vHPV, Gardasil®), were approved in July 2016 and April 2017, respectively. A 9-valent HPV vaccine (9vHPV, Gardasil®9) was licensed in May 2018. The domestic bivalent Innovax’s (Cecolin®) and Walvax’s HPV vaccines (Walrinvax®) were approved in December 2019 and March 2022, respectively. Each of the five vaccines is licensed for different age ranges at initial, with Cervarix® recommended for ages of 9–25, Gardasil® recommended for ages 20–45, Gardasil®9 recommended for ages 16–26, and the two domestic bivalent HPV vaccines are recommended for individuals aged 9–45 and 9–30, respectively. While currently all the HPV vaccines have been proved safe for use in women aged 9–45 years in China (excluding Walrinvax®) and have not yet been included in the National Immunization Programme [15]. Immunization of women aged 9–26 is the priority in Chinese guidelines. The current supply of HPV vaccine is insufficient to cover the target population to prevent cancer; thus, there are insufficient vaccines available for the implementation of vaccination to address CA, especially the quadrivalent (Gardasil®) and the nonvalent (Gardasil®9) HPV vaccines, the only two licensed HPV vaccines that protect against CA [14]. The unaffordable price ($370–$595) has largely limited vaccine uptake by individuals in high-risk populations. Hence, an affordable HPV-6/11 vaccine for preventing CA will be applicable to the population at high risk for STDs and may be a potential method to improve the disease burden associated with CA in the future.

At present, one HPV 6/11 bivalent vaccine candidate has specifically been designed to protect against genital warts and other HPV 6/11-related diseases. This vaccine has been preliminarily proven to be well tolerated and demonstrated robust immunogenicity in a phase 1 clinical study (NCT02405520) and is currently being evaluated in a phase 2 clinical trial (NCT02710851) [16]. Despite being in the early stages of validation, the introduction of such a vaccine could potentially contribute to a lower prevalence of CA in high-risk sexually transmitted infections (STIs) populations. The question arises, however, we are interested in exploring whether a vaccine specifically for the prevention of CA is needed when there is already an HPV vaccine for the prevention of both cancer and CA, and whether STD clinic attendees (who are at high risk for STIs, but have a lower chance of receiving quadrivalent or nonvalent HPV vaccines) will be the target potential population? In general, the purpose of this study was to investigate the attitudes toward HPV vaccination for CA and the willingness to undergo vaccination among STD clinic attendees in China.

Materials and methods

Design and participants

A cross-sectional survey covering the knowledge of, attitude toward, and willingness to undergo the HPV vaccine for CA was conducted at the Dermatology Hospital of Southern Medical University and the Affiliated Hospital of Nantong University from May to September 2017. Both centers were visited by people with STIs requiring treatment or who suspected they had an STI. We recruited all individuals who visited the two STD clinics from May to September 2017. STD clinic attendees aged 18 years or older were consecutively included after consent and were asked to complete a self-administered questionnaire designed by a research team comprising physicians and public health and sociology experts, and revised after a pre-survey evaluation in January 2017.

Data collection and questionnaire

The questionnaire covering knowledge, attitude, and practices (KAP) regarding CA and HPV vaccines/cervical cancer vaccines, included information on sociodemographic characteristics, sexual behaviors, history of infection with HPV, HIV and syphilis, the individual’s self-perception on their knowledge of CA and the HPV vaccines/cervical cancer vaccines, and the acceptance of the HPV vaccine for CA and their behavioral willingness regarding vaccination.

The study protocol was reviewed and approved by the Ethics Committees of Guangdong Provincial Dermatology Hospital, Guangzhou, China on November 21, 2016 (approval number: GDDHLS-2016112102). After informed consent was obtained, all eligible participants completed the paper questionnaire independently in a private consulting room, and assistance was provided if required. The questionnaire took approximately 10 min to complete. The collected data were input separately by two different researchers and checked by a third researcher to ensure accuracy.

Statistical analysis

Descriptive statistics were used to compile the participants’ demographic characteristics and their sexual behaviors, history of STIs, and knowledge of CA and HPV vaccines (cervical cancer vaccines) and attitude toward the HPV vaccine for CA. A chi-square test was used to compare categorical variables and test the differences between males and females based on these items. The crude odds ratio (OR) was first proposed in a univariate analysis. The univariate logistic regression analysis began with a full set of sociodemographic, sexual behaviors, history of STIs, knowledge of CA and HPV vaccines /cervical cancer vaccines, and attitude toward the HPV vaccine for CA, and behavioral willingness regarding vaccination to evaluate the associations with the willingness to undergo vaccination and attitudes toward the HPV vaccine for CA. Other variables with a P value < 0.05 and a dummy variable P value < 0.2 in the univariate models were entered into a multivariate logistic regression model to explore factors associated with the HPV vaccine for CA acceptance. The adjusted odds ratio (AOR) and the corresponding 95% confidence intervals (CI) were calculated to assess the results of the regression model. Data regarding the average costs per visit were normally distributed, and the results were analyzed using Student’s t test; otherwise, the rank sum test was used. Statistical analyses were conducted using SAS 9.4, with the significance threshold of a P value of 0.05.

Attitude toward the HPV vaccine for CA: The attitude section of the questionnaire included 3 questions on the individual’s view on the HPV vaccine for CA safety and effectiveness and their willingness to recommend vaccination; the questions were on a six-point scale for assessing individual attitudes (5 points - Strongly Agree, 4 points - Agree, 3 points - Neutral, 2 points - Disagree, 1 point - Strongly Disagree, 0 points - Unclear). Participants were considered to have a positive attitude toward the HPV vaccine for CA when they scored more than 9 points on the 3 attitude questions.

Result

Demographic characteristics, sexual behaviors, and history of STIs

After excluding 40 incomplete questionnaires, 274 (87.3%) participants were included in the study, among whom 174(63.5%) were from Guangdong and 100(36.5%) were from Jiangsu. The detailed baseline information of the included participants was summarized in Table 1, including the sociodemographic characteristics, sexual behaviors, and history of STIs. The participants were distributed evenly by sex (55.5% vs. 44.5%), and the median age was 28 years old (IQR: 24.0–34.0). Furthermore, 88.0% of participants were heterosexual. Approximately half of the participants were married (55.8%), while 80.4% had fixed sexual partners over the past 12 months. The prevalence of CA among the STD clinic attendees was 44.5% (122/274). In 122 STD clinic attendees with a history of CA, 69.7% (85/122) currently had CA, and 56.6% (69/122) had a history of recurrent CA, with an interval of 1–3 months (65.7%) in about two-thirds of them. Furthermore, 11.0% of participants self-reported that they were living with HIV, and 4.7% had been previously diagnosed with syphilis.

Table 1 Sociodemographic characteristics, sexual behaviors, and STIs history in STD clinic attendees
Full size table

Among the participants, males had a higher salary than females (χ2 = 10.9609, p = 0.0119). In addition, male STD clinic attendees were more likely than female STD clinic attendees to have engaged in risky sexual behaviors in the past 12 months, such as having temporary sexual partners (χ2 = 14.5440, p = 0.0001), having over 5 sexual partners (χ2 = 11.3759, p = 0.0034), and participating in sexual intercourse under the influence of alcohol (χ2 = 8.6812, p = 0.0032). Additionally, male STD clinic attendees were more likely than females to engage in unhealthy life behaviors, such as frequent drinking (χ2 = 23.3827, p < 0.0001) and smoking (χ 2 = 65.4037, p < 0.0001). Compared with female STD clinic attendees, male STD clinic attendees were more likely to have been diagnosed with syphilis. (χ2 = 6.9761, p = 0.0306). There were no significant sex-based differences in self-reported HIV testing status or history of CA.

Self-perception on knowledge of CA and HPV vaccines

Table 2 showed the participants’ self-perception on their knowledge of CA and HPV vaccines. Approximately 72.3% of STD clinic attendees knew about CA and 42.0% of them had heard about the HPV vaccines /cervical cancer vaccines, with the internet being the main source of this information (around 46.1%), followed by the doctors (37.9%), WeChat (19.3%), and television/broadcast (9.3%) (Fig. 1). However, a sizable proportion of CA disease-aware STD clinic attendees still had poor knowledge of the disease; 39.4–52.2% of STD clinic attendees lacked knowledge of the transmission routes, symptoms and risks associated with CA or of the treatments available for CA.

Table 2 Self-perception on knowledge of CA and vaccines in STD clinic attendees
Full size table
Fig. 1
figure 1

The sources of CA and vaccine knowledge. The x axis listed difference sources of knowledge. The y axis represents the percentages of participants getting knowledge with these sources. Participants were allowed to select multiple options when answering questions about their current sources of knowledge on CA and vaccines and their preferred future sources of information on the same topics

Full size image

Although 67.8% of them had heard of HPV infection, 40.1% were unaware of the connection between CA and HPV. STD clinic attendees seemingly had poor behavioral willingness toward the HPV vaccine; only 18.5% of the STD clinic attendees evaluated in this study had friends or family members who had received the HPV vaccines/cervical cancer vaccines, and 21.0–30.6% had proactively obtained knowledge regarding HPV vaccination, receiving related education or discussing with others.

Among the participants, female STD clinic attendees were more likely than male STD clinic attendees to hear of HPV vaccines/cervical cancer vaccines (χ2 = 7.6160, p = 0.0058). In addition, there was no significant difference between males and females in regards to knowledge of CA and HPV vaccines/cervical cancer vaccines and behavioral willingness toward vaccination.

Factors associated attitudes toward the HPV vaccine for CA and willingness to undergo vaccination

A high willingness to undergo the HPV vaccine for CA was observed (85.8%, 235/274), in our study, and no sex differences were present (male vs. female: 87.7% vs.84.2%). However, only 95 (34.7%) of 274 participants had a positive attitude toward the HPV vaccine for CA. Tables 3 and 4 showed the factors associated with attitudes toward the HPV vaccine for CA and willingness to undergo vaccination for CA. The univariate logistic regression analysis revealed that, among STD clinic attendees, the 9 variables “Age”, “Self-identified sexual orientation”, “Sexual intercourse under the influence of alcohol in the past 12 months”, “History of CA”, “HIV testing status”, “Ever heard of CA”, “Ever heard of HPV infection”, “Ever heard of HPV vaccines/cervical cancer vaccine”, and “Have you proactively learned about CA” were later evaluated in the multivariate logistic regression analysis to predict STD clinic attendees’ willingness to receive the HPV vaccine for CA. A similar procedure was also applied to attitudes toward the HPV vaccine for CA among STD clinic attendees.

Table 3 Willingness to undergo CA vaccination and attitudes toward CA vaccination in STD clinic attendees with different characteristics
Full size table
Table 4 Vaccination willingness and attitudes of STD clinic attendees with different awareness levels of CA and vaccines
Full size table

In the multivariate analysis, among STD clinic attendees, those who had heard of CA demonstrated an over three-fold higher willingness to receive the HPV vaccine for CA (AOR = 3.14, 95% CI: 1.29–7.63, p = 0.0114). Additionally, the multivariate logistic regression model analysis indicated that STD clinic attendees who were aware of the relationship between HPV and CA (AOR = 2.56, 95% CI: 1.31-5.00, p = 0.0060), had heard of the HPV vaccines/ cervical cancer vaccines (AOR = 1.90, 95% CI: 1.02–3.54, p = 0.0444) and had proactively discussed CA or the vaccine with others (AOR = 1.95, 95% CI: 1.00-3.79, p = 0.0488) had better attitudes toward the HPV vaccine for CA.

Healthcare costs for diagnostics and treatment for CA among STD clinic attendees and willingness to pay for the HPV vaccine for CA

A total of 93 STD clinic attendees with CA participated in the section on healthcare costs. Figure 2 showed the average cost for CA per visit according to different regions and sexes. The mean cost associated with diagnostics and treatment for CA per visit was $509.55 among STD clinic attendees from Guangdong, which was lower than the mean cost in Jiangsu ($625.27).

Fig. 2
figure 2

The costs for per visit of STD clinic attendees. *p < 0.05. The median lines in each box represents the average cost in each group; the lower and upper lines of the box represent the lower and upper values of 95% confidence interval of average cost; the lines beyond the boxes represents the range of cost in each group. The blue, red and grey boxes represent the group of females, male and overall STD clinic attendees respectively

Full size image

Additionally, Fig. 3 revealed the acceptable payment ranges for HPV vaccination among participants, over half of the participants (52.5%) expected the vaccination to cost less than $90.

Fig. 3
figure 3

The acceptable range of payment for HPV vaccination. The x axis represents the acceptable range of payment for HPV vaccination. The y axis represents percentage of participants

Full size image

Discussion

To the best of our knowledge, studies addressing how STD clinic attendees (both females and males) in China view the HPV vaccine for CA are rare. Here, we aimed to investigate willingness and attitude toward the HPV vaccine for CA among STD clinic attendees, and found that willingness and attitude toward the HPV vaccine for CA were positively associated with knowledge.

In our study, the HPV vaccine for CA willingness among STD clinic attendees in Guangdong and Jiangsu was high (85.8%,235/274), and participants were willing to adopt protective behaviors against CA. Under half of the STD clinic attendees (34.7%) had a positive attitude toward the HPV vaccine for CA. The results revealed that awareness of CA was significantly related to willingness to undergo the HPV vaccine for CA among STD clinic attendees. STD clinic attendees who were aware of the HPV vaccine and the relationship between HPV and CA, and had proactively discussed CA or the vaccine with others were more likely to have positive attitudes toward the HPV vaccine for CA. This finding implied that the knowledge of CA and related education was essential for vaccination willingness and positive attitudes, consistent with the findings of previous studies [17,18,19]. Although a relevant stable marital status and sexual behavior among participants were showed (55% of them were married and 80% of them had fixed sexual partners), the rate of individuals who had a history of CA was high (almost 50%) in our study, which might explain the observed high willingness towards vaccination.

Even among STD clinic attendees at high risk for CA, although most (72.3%) had heard of CA and 67.8%  had heard of HPV infection, 40.1% still were unaware of the connection between CA and HPV. The proportion of STD clinic attendees heard of HPV infection (67.8%) was higher than that found among university students in China (51.1%) [17], but lower than that of males recruited at a sexual health clinic in Italy (74.9%) [20], and significantly lower than that in MSM populations in Western countries (73–93%) [20,21,22]. Notably, although the participants were attendees of two STD clinics and a considerable proportion of them reported a history of CA (44.53%), the proportion of STD clinic attendees aware of the connection between CA and HPV (59.9%) was consistent with that of studies conducted on university students in China (54.0–67.5%) [17, 23, 24]. This result indicates that most STD clinic attendees have limited knowledge of the association between CA and HPV. The self-perception on knowledge of CA and HPV vaccines in STD clinic attendees was in a middle level. Other studies have shown that the more individuals know about HPV manifestations, signs, and forms of prevention, the better their health outcomes will be [25]. Educational programs can potentially broaden knowledge of the association between HPV and CA in the future, and improve knowledge of CA transmission routes, symptoms, risks, and treatments [26].

Our study data showed that patients with CA have a large financial burden of medical care, with the mean cost associated with diagnostics and treatment for CA per visit in Guangdong and Jiangsu being $509.55 and $625.27 respectively. A real-world cost analysis of England showed that lifetime costs per patient diagnosed with anogenital warts was equal to £872 (£884 and £856 for men and women, respectively) [27]. In Peru, given a population of 18.4 million adults between 18 and 60 years of age and a CA prevalence of 2.28%, the annual cost of treating CA was 25.1 million USD (uncertainty interval 16.9, 36.6) [28]. The cost per case of managing CA in Morocco, including recurrence, was estimated at €207–272 for women and €206–233 for men and the total annual cost of medical consultations for CA in Morocco ranged from €310,828 − 404,102 [29]. The annual incidence of CA in Mexico was estimated to be 547,200 cases, with an annual cost of $195 million USD, it also suggested that CA had a significant impact on public health [30].In our study, over half of STD clinic attendees expected the vaccination to cost less than $90.

Currently, all available HPV vaccines are only accessible to recommended-age females in China, so the affordability and accessibility of HPV vaccination are the priority challenges in the STD high-risk populations, especially among men. Therefore, another kind of HPV vaccine that targets solely HPV 6/11 for preventing CA, could play a role in addressing the issue of inadequate supplies and high price of current licensed HPV vaccines, to meet potential requirements of specific populations. Meanwhile, it should also be noted that an HPV-6/11 vaccine for CA may convey the message against STI, which might stigmatize and influence the acceptability of such a vaccine. It was encouraging that acceptance of the HPV vaccine for CA was high in our survey of STD clinic attendees and previous survey of MSM [31].

CA is a kind of benign lesion that is largely ignored among diseases caused by HPV infection (typically cancer); however, it could also lead to a decline in quality of life in the long term and has caused an unignorable disease burden in some populations. This study revealed that the willingness to be vaccinated and positive attitudes towards the HPV vaccine for CA are significantly linked to knowledge among STD clinic attendees, a very important group at high risk for STIs and HIV infection in China, to provide clues for future methods to address CA-associated health issues.

Limitations

First, in this study, a preliminary exploration was conducted, but the deeper factors influencing the self-perception on knowledge of CA, acceptability of the HPV vaccine for CA and the impact of education on health were not considered. Second, although self-perception regarding knowledge of CA and HPV vaccines/ cervical cancer vaccines among STD clinic attendees was at a middle level, they were willing to accept the HPV vaccine for CA for a reasonable price. We think that an HPV-6/11 vaccine targeting CA might supplement existing HPV prevention strategies, potentially addressing the varied needs of different populations more effectively. However, more studies involving the implementation issues are warranted to be conducted, including but not limited to the cost-effectiveness analysis. Finally, the survey was conducted in 2017 (over 7 years ago) and the results of the survey may differ from the current situation, however, this difference may be very limited. For instance, the existing supply of several HPV vaccines remains in shortage; although the clinical guidelines for the treatment of CA in China in 2021 suggest that the quadrivalent and nonavalent vaccines containing HPV 6 and 11 are recommended for the prevention of CA, the current HPV vaccination strategy available in China until 2024 remains to prevent cervical cancer and not to recommend vaccination for the male population [32]. Over the past several years, people have been exhausted from coping with the COVID-19 pandemic, and the initiatives to pursue issues related to other infectious diseases were neglected and lacked (especially relatively benign lesions, such as CA). Therefore, although our study has some limitations in terms of timeliness, we believe that our results are valuable to CA prevention and control policy-makers in China.

Conclusions

The willingness to undergo vaccination and attitudes toward the HPV vaccine for CA were positively associated with knowledge, and educational programs can have the potential to solve the barriers to the HPV vaccine for CA willingness and attitudes in the future, especially among individuals at high risk for STDs with negative attitudes.

Data availability

Authorization to access the data may be considered by the authors upon reasonable requests. Requests to access these datasets should be directed to the corresponding author, xuqi-ren@ntu.edu.cn.

Abbreviations

HPV:

Human papillomavirus

CA:

Condyloma acuminata

STD:

Sexually transmitted disease

STIs:

Sexually transmitted infections

IQR:

Interquartile range

OR:

Crude odds ratio

AOR:

Adjusted odds ratios

CI:

Confidence intervals

LLMICs :

low-income and lower-middle-income countries

References

  1. De Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90. https://doi.org/10.1016/S2214-109X(19)30488-7.

    Article  PubMed  Google Scholar 

  2. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. https://doi.org/10.1016/S2214-109X(19)30482-6.

    Article  PubMed  Google Scholar 

  3. Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S849–55. https://doi.org/10.1093/cid/civ813.

    Article  PubMed  Google Scholar 

  4. Giuliano AR, Botha MH, Zeier M, Abrahamsen ME, van der Glashoff RH, et al. High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial. J Acquir Immune Defic Syndr. 2015;68(2):227–35. https://doi.org/10.1097/QAI.0000000000000425.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Siqueira JD, Curty G, Xutao D, Hofer CB, Machado ES, Seuánez HN, et al. Composite analysis of the virome and bacteriome of HIV/HPV co-infected women reveals proxies for immunodeficiency. Viruses. 2019;11(5):422. https://doi.org/10.3390/v11050422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lacey CJN, Guimera N, Garland SM. Chapter 10 - low-risk human papillomavirus: genital warts, cancer and respiratory papillomatosis [M]//JENKINS D, BOSCH F X. Human Papillomavirus. Acad Press. 2020;165–78. https://doi.org/10.1016/B978-0-12-814457-2.00010-6.

  7. Dareng EO, Adebamowo SN, Famooto A, Olawande O, Odutola MK, Olaniyan Y, et al. Prevalence and incidence of genital warts and cervical human papillomavirus infections in Nigerian women. BMC Infect Dis. 2019;19(1):27. https://doi.org/10.1186/s12879-018-3582-y.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39. https://doi.org/10.1186/1471-2334-13-39.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yue X, Gong X, Li J, Teng F, Jiang N, Men P, et al. Epidemiological features of condyloma acuminatum in national sexually transmitted disease surveillance sites in China from 2008 to 2016. Chin J Dermatol. 2017;50(5):3215. https://doi.org/10.3760/cma.j.issn.0412-4030.2017.05.003.

    Article  Google Scholar 

  10. Wei F, Guo M, Huang S, Li M, Cui X, Su Y, et al. Sex differences in the incidence and clearance of anogenital human papillomavirus infection in Liuzhou, China: an observational cohort study. Clin Infect Dis. 2020;70(1):82–9. https://doi.org/10.1093/cid/ciz168.

    Article  PubMed  Google Scholar 

  11. Pirotta M, Ung L, Stein A, Conway EL, Mast TC, Fairley CK, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect. 2009;85(7):508–13. https://doi.org/10.1136/sti.2009.037028.

    Article  CAS  PubMed  Google Scholar 

  12. Karaali MG, Manav V. Evaluation of sleep quality in patients with genital and non-genital cutaneous warts: a prospective controlled study. Dermatol Pract Concept. 2022;12(4):e2022167. https://doi.org/10.5826/dpc.1204a167.

    Article  PubMed  PubMed Central  Google Scholar 

  13. WHO. Human Papillomavirus (HPV) vaccination coverage. https://immunizationdata.who.int/global/wiise-detail-page/human-papillomavirus-(hpv)-vaccination-coverage?CODE=Global&YEAR. Accessed 11 April 2024.

  14. Wong LP, Han L, Li H, Zhao J, Zhao Q, Zimet GD. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects. Hum Vaccin Immunother. 2019;15(7–8):1533–40. https://doi.org/10.1080/21645515.2019.1611157.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020;8(10):e1335–44. https://doi.org/10.1016/S2214-109X(20)30277-1.

    Article  PubMed  Google Scholar 

  16. Mo ZJ, Bi ZF, Sheng W, Chen Q, Huang T, Li MQ, et al. Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: a dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Hum Vaccin Immunother. 2022;18(6):2092363. https://doi.org/10.1080/21645515.2022.2092363.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dai Z, Si M, Su X, Wang W, Zhang X, Gu X, et al. Willingness to human papillomavirus (HPV) vaccination and influencing factors among male and female university students in China. J Med Virol. 2022;94(6):2776–86. https://doi.org/10.1002/jmv.27478.

    Article  CAS  PubMed  Google Scholar 

  18. Li X, Cao X, Li Z, Yang Y, Li M, Feng B, et al. Human papillomavirus awareness and vaccine acceptability among men who have sex with men from mainland China. Sci Rep. 2019;9(1):8763. https://doi.org/10.1038/s41598-019-45258-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Trucchi C, Amicizia D, Tafuri S, Sticchi L, Durando P, Costantino C, et al. Assessment of Knowledge, attitudes, and propensity towards HPV vaccine of young adult students in Italy. Vaccines (Basel). 2020;8(1):74. https://doi.org/10.3390/vaccines8010074.

    Article  PubMed  Google Scholar 

  20. Giuliani M, Vescio MF, Donà MG, Latini A, Frasca M, Colafigli M, et al. Perceptions of human papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation. Hum Vaccin Immunother. 2016;12(6):1542–50. https://doi.org/10.1080/21645515.2015.1115935.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nadarzynski T, Frost M, Miller D, Wheldon CW, Wiernik BM, Zou H, et al. Vaccine acceptability, uptake and completion amongst men who have sex with men: a systematic review, meta-analysis and theoretical framework. Vaccine. 2021;39(27):3565–81. https://doi.org/10.1016/j.vaccine.2021.05.013.

    Article  PubMed  Google Scholar 

  22. Zeitoun JD, Duclos A, de Parades V, Lefèvre JH. Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. Hum Vaccin Immunother. 2020;16(12):3119–22. https://doi.org/10.1080/21645515.2020.1756151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chiang VC, Wong HT, Yeung PC, Choi YK, Fok MS, Mak OI, et al. Attitude, acceptability and knowledge of HPV vaccination among Local University Students in Hong Kong. Int J Environ Res Public Health. 2016;13(5):486. https://doi.org/10.3390/ijerph13050486.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chen H, Zhou J, Huang Q, Si MY, Su XY, Li J. Status of human papillomavirus vaccination and knowledge, attitudes, and influencing factors towards human papillomavirus and its vaccines among University students in Western China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021;43(4):545–50. https://doi.org/10.3881/j.issn.1000-503X.13153. Chinese.

    Article  PubMed  Google Scholar 

  25. Vieira VK, Wendt GW, Ferreto LED, Pascotto CR, Lucio LC. University students’ knowledge about the relation between human papillomavirus (HPV) and head and neck and oral cancers. Asian Pac J Cancer Prev. 2022;23(8):2719–26. https://doi.org/10.31557/APJCP.2022.23.8.2719.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Boitano TKL, Ketch PW, Scarinci IC, Huh WK. An update on human papillomavirus vaccination in the United States. Obstet Gynecol. 2023;141(2):324–30. https://doi.org/10.1097/AOG.0000000000005056.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fabiano G, Marcellusi A, Mennini FS, Sciattella P, Favato G. Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis. Eur J Health Econ. 2023;24(1):75–80. https://doi.org/10.1007/s10198-022-01453-x.

    Article  CAS  PubMed  Google Scholar 

  28. Saldarriaga EM, Cárcamo CP, Babigumira JB, García PJ. The annual costs of treating genital warts in the Public Healthcare Sector in Peru. BMC Health Serv Res. 2021;21(1):1092. https://doi.org/10.1186/s12913-021-07120-w.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Berrada M, Holl R, Ndao T, Benčina G, Dikhaye S, Melhouf A, et al. Healthcare resource utilization and costs associated with anogenital warts in Morocco. Infect Agent Cancer. 2021;16(1):64. https://doi.org/10.1186/s13027-021-00403-1.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Domenech-Viñolas M, León-Maldonado L, Ramírez-Palacios P, Flores YN, Granados-García V, Brown B et al. Incidence, psychosocial burden, and economic impact of genital warts in Mexico. Salud Publica Mex. 2018 Nov-Dec;60(6):624–32. English. https://doi.org/10.21149/10008.

  31. Ren X, Qiu L, Ke W, Zou H, Liu A, Wu T. Awareness and acceptance of HPV vaccination for condyloma acuminata among men who have sex with men in China. Hum Vaccin Immunother. 2022;18(6):2115267. https://doi.org/10.1080/21645515.2022.2115267.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Chinese Society of Dermatology and Venereology, Association CD. Chinese Association of Rehabilitation Dermatology and Venereology. Guideline for the Clinical Management of Anogenital Warts in China (2021) [J]. Clin J Derm. 2021;35(04):359–74. https://doi.org/10.13735/j.cjdv.1001-7089.202101183.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are hugely greatly to all those who helped to design the self-administered questionnaire. We thank the employees of Xiamen Innovax for their help in the design of the project. We also thank you for the financial support from Xiamen Innovax Biotech Co., Ltd. (XNBH00030740) and Jiangsu Provincial Research Hospital (YJXYY202204-YSB41). The funder had no role in the implementation of the project, data collection and analysis, and decision to publish.

Funding

The work was supported by the Xiamen Innovax Biotech Co., Ltd. [XNBH00030740]. Additionally, this study was supported by grants from Jiangsu Provincial Research Hospital: YJXYY202204-YSB41.

Author information

Author notes

  1. Joint first-authorship: Anqi-Liu and Jiali-Quan.

Authors and Affiliations

  1. Department of Dermatology, Affiliated Hospital of Nantong University, Nantong, China

    Anqi-Liu &  Xuqi-Ren

  2. State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, China

    Jiali-Quan,  Lingxian-Qiu,  Yue-Huang &  Ting-Wu

  3. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, Xiamen University, Xiamen, China

    Jiali-Quan,  Lingxian-Qiu,  Yue-Huang &  Ting-Wu

  4. Department of Sexually Transmitted Diseases, Dermatology Hospital, Southern Medical University, Guangzhou, China

    Wujian-Ke &  Xuqi-Ren

  5. School of Public Health, Fudan University, Shanghai, China

    Huachun-Zou

Authors
  1. Anqi-Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiali-Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingxian-Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yue-Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wujian-Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huachun-Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ting-Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xuqi-Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AQ-L, XQ-R, WJ-K, TW, and HC-Z designed and coordinated the study. XQ-R monitored the implementation of the project and the collection of the data. XQ-R, JL-Q, LX-Q, YH discussed and analyzed the data, and JL-Q prepared the manuscript. All authors critically reviewed the manuscript and approved the final version.

Corresponding authors

Correspondence to Yue-Huang or Xuqi-Ren.

Ethics declarations

Ethical approval

The study protocol was reviewed and approved by the Ethics Committees of Guangdong Provincial Dermatology Hospital, Guangzhou, China (GDDHLS-2016112102).

Conflict of interest

No potential conflict of interest was reported by the author(s).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anqi-Liu, Jiali-Quan, Lingxian-Qiu et al. Attitudes toward an HPV vaccine for condyloma acuminata and willingness to undergo vaccination among STD clinic attendees in China: Focus on STI prevention with HPV vaccine. BMC Public Health 24, 1610 (2024). https://doi.org/10.1186/s12889-024-18904-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12889-024-18904-0

Keywords

BMC Public Health

ISSN: 1471-2458

Contact us